Jessica Fye
Stock Analyst at JP Morgan
(4.43)
# 339
Out of 5,008 analysts
205
Total ratings
60.94%
Success rate
15.08%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Maintains: Overweight | $53 → $52 | $42.50 | +22.35% | 6 | Sep 24, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $116 → $121 | $106.06 | +14.09% | 13 | Sep 22, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $53 → $77 | $73.74 | +4.42% | 4 | Sep 12, 2025 | |
| ALKS Alkermes | Maintains: Neutral | $34 → $35 | $30.95 | +13.09% | 7 | Sep 9, 2025 | |
| LEGN Legend Biotech | Maintains: Overweight | $77 → $78 | $31.41 | +148.33% | 3 | Aug 25, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $48 → $49 | $68.94 | -28.92% | 6 | Aug 25, 2025 | |
| INCY Incyte | Maintains: Neutral | $67 → $73 | $87.17 | -16.26% | 8 | Aug 22, 2025 | |
| INSM Insmed | Maintains: Overweight | $111 → $135 | $162.32 | -16.83% | 9 | Aug 20, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $254 → $260 | $209.84 | +23.90% | 15 | Aug 19, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $60 → $63 | $66.02 | -4.57% | 14 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $348 → $475 | $459.58 | +3.36% | 8 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $321 → $345 | $341.62 | +0.99% | 3 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $515 → $517 | $410.28 | +26.01% | 9 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $108 → $113 | $54.70 | +106.58% | 4 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $330 | $456.84 | -27.76% | 17 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $33 → $26 | $27.34 | -4.90% | 13 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $13 | $6.95 | +87.05% | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $50 | $34.22 | +46.11% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $28 | $14.16 | +97.74% | 4 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $209 | $137.32 | +52.20% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $24 | $14.90 | +61.07% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $15.80 | +89.87% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $13 | $27.31 | -52.40% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $58.00 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $9.92 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $3.09 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $19.27 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.45 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.61 | +1,270.72% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $1.52 | +360.53% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $7.96 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $9.22 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $11.08 | - | 1 | Feb 8, 2018 |
Crinetics Pharmaceuticals
Sep 24, 2025
Maintains: Overweight
Price Target: $53 → $52
Current: $42.50
Upside: +22.35%
BioNTech SE
Sep 22, 2025
Maintains: Neutral
Price Target: $116 → $121
Current: $106.06
Upside: +14.09%
Mirum Pharmaceuticals
Sep 12, 2025
Maintains: Overweight
Price Target: $53 → $77
Current: $73.74
Upside: +4.42%
Alkermes
Sep 9, 2025
Maintains: Neutral
Price Target: $34 → $35
Current: $30.95
Upside: +13.09%
Legend Biotech
Aug 25, 2025
Maintains: Overweight
Price Target: $77 → $78
Current: $31.41
Upside: +148.33%
Ionis Pharmaceuticals
Aug 25, 2025
Maintains: Neutral
Price Target: $48 → $49
Current: $68.94
Upside: -28.92%
Incyte
Aug 22, 2025
Maintains: Neutral
Price Target: $67 → $73
Current: $87.17
Upside: -16.26%
Insmed
Aug 20, 2025
Maintains: Overweight
Price Target: $111 → $135
Current: $162.32
Upside: -16.83%
Ascendis Pharma
Aug 19, 2025
Maintains: Overweight
Price Target: $254 → $260
Current: $209.84
Upside: +23.90%
Halozyme Therapeutics
Aug 7, 2025
Maintains: Neutral
Price Target: $60 → $63
Current: $66.02
Upside: -4.57%
Aug 6, 2025
Maintains: Overweight
Price Target: $348 → $475
Current: $459.58
Upside: +3.36%
Jul 17, 2025
Maintains: Overweight
Price Target: $321 → $345
Current: $341.62
Upside: +0.99%
Jul 14, 2025
Maintains: Overweight
Price Target: $515 → $517
Current: $410.28
Upside: +26.01%
Jul 14, 2025
Maintains: Overweight
Price Target: $108 → $113
Current: $54.70
Upside: +106.58%
Jul 8, 2025
Maintains: Overweight
Price Target: $350 → $330
Current: $456.84
Upside: -27.76%
May 22, 2025
Maintains: Underweight
Price Target: $33 → $26
Current: $27.34
Upside: -4.90%
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $6.95
Upside: +87.05%
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $34.22
Upside: +46.11%
Apr 10, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $14.16
Upside: +97.74%
Feb 26, 2025
Maintains: Overweight
Price Target: $200 → $209
Current: $137.32
Upside: +52.20%
Jan 7, 2025
Maintains: Overweight
Price Target: $28 → $24
Current: $14.90
Upside: +61.07%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $15.80
Upside: +89.87%
Mar 26, 2024
Maintains: Neutral
Price Target: $6 → $13
Current: $27.31
Upside: -52.40%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $58.00
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $9.92
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $3.09
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $19.27
Upside: -
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.45
Upside: -
Apr 19, 2021
Initiates: Overweight
Price Target: $22
Current: $1.61
Upside: +1,270.72%
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $1.52
Upside: +360.53%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $7.96
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $9.22
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $11.08
Upside: -